Depinar, a drug that potentially inhibits the binding and entry of COVID‐19 into host cells based on computer-aided studies

Meysam Yazdani , Jafar Khezri, Nastaran Hadizadeh, Javad Zamani Amir Zakaria, Mousa Naderi, Sahar Mahmoodian, Ali Asghar Karkhanei, Farideh Razi, Mohammad Hossein Sanati , Ehsan Hashemi


Background and purpose: The new coronavirus (Covid-19) has resulted in great global concerns. Due to the mortality of this virus, scientists from all over the world have been trying to employ different strategies                         to tackle down this concern. This virus enters cells via phagocytosis through binding to the                            angiotensin-converting enzyme II receptor. After invading the body, it can stay hidden in there for a period of up to 24 days (incubation period).

Experimental approach: In this report, by the use of in silico studies we selected several FDA-approved compounds that possess antiviral properties. We chose the viral Spike protein as the target of drug compounds and carried out the screening process for the FDA databank in order to find the most effective ligand.

Findings/Results: The results from dock and MD revealed 10 compounds with high affinity to the                    receptor-binding domain motif of S protein. The best inhibitors were the ingredients of Depinar, which managed to effectively block the interactions between cells and virus.

Conclusion and implication: The results of this study were approved by in silico studies and due to the lack of time; we did not test the efficiency of these compounds through in vitro and in vivo studies. However, the selected compounds are all FDA approved and some are supplements like vitamin B12 and don’t cause any side effects for patients.




Keywords: Corona; Covid-19; Depinar; Docking-based virtual screening; Molecular dynamics.

Full Text:



Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.


Velavan P, Meyer CG. The COVID‐19 epidemic. Trop Med Int Health. 2020;25(3):278-280.

DOI: 10.1111/tmi.13383.

Blanco-Lobo P, Nogales A, Rodríguez L, Martínez-Sobrido L. Novel approaches for the development of live attenuated influenza vaccines. Viruses. 2019;11(2):190-224.

DOI: 10.3390/v11020190.

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020;75(18):2352-2371.

DOI: 10.1016/j.jacc.2020.03.031.

Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020;177:104759,1-4.

DOI: 10.1016/j.antiviral.2020.104759.

Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT findings in patients with corona virus disease 2019 and its relationship with clinical features. Invest Radiol. 2020;55(5):257-261.

DOI: 10.1097/RLI.0000000000000670.

Rossman H, Keshet A, Shilo S, Gavrieli A, Bauman T, Cohen O, et al. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys. Nat Med. 2020;26:634-638.

DOI: 10.1038/s41591-020-0857-9.

Tomasi D. Coronavirus disease (COVID-19), a socioepidemiological review-2. Vermont Academy of Arts and Sciences. VAAS. 2020;1:1-8.

Epidemiology working group for NCIP epidemic response, chinese center for disease control and prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.

DOI: 10.3760/cma.j.issn.0254-6450.2020.02.003.

Wong G, Liu W, Liu Y, Zhou B, Bi Y, Gao GF. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe. 2015;18(4):398-401.

DOI: 10.1016/j.chom.2015.09.013.

Ki M. 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health. 2015;37:e2015033,1-4.

DOI: 10.4178/epih/e2015033.

Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):taaa021.

DOI: 10.1093/jtm/taaa021.

Kennedy T. Managing the drug discovery/development interface. Drug Discov Today. 1997;2(10):436-444.

DOI: 10.1016/S1359-6446(97)01099-4.

Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff (Millwood). 2006;25(2):420-428.

DOI: 10.1377/hlthaff.25.2.420.

Mullard A. New drugs cost US $2.6 billion to develop. Nature Rev Drug Discov. 2014;13:877.

DOI: 10.1038/nrd4507.

Contini A. Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins. ChemRxiv. 2020:1-6. Available in:

Dayer MR. Old drugs for newly emerging viral disease, COVID-19: bioinformatic prospective. 2020;arXiv:2003.04524:116.


Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232-1244.

DOI: 10.7150/ijbs.24612.

Deng X, Yu X, Pei J. Regulation of interferon production as a potential strategy for COVID-19 treatment. 2020;arXiv:2003.00751:1-9.Available in:

Macchiagodena M, Pagliai M, Procacci P. Inhibition of the main protease 3CL-pro of the coronavirus disease 19 via structure-based ligand design and molecular modeling. 2020;arXiv:2002.09937 :1-28.

Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. ChemRxiv. 2020:1-8. Available in: https : // _from_ FDA_ Approved_ Drugs/ 11860011/2.

Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci. 2020;258:118205,1-14.

DOI: 10.1016/j.lfs.2020.118205.

Haider Z, Subhani MM, Farooq MA, Ishaq M, Khalid M, Khan RSA, et al. in silico discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 using pharmacophore and molecular docking based virtual screening from ZINC database. 2020.

DOI: 10.20944/preprints202002.0431.v1.

Talluri S. Molecular docking and virtual screening based prediction of drugs for COVID-19. Comb Chem High Throughput Screen. 2020.

DOI: 10.2174/1386207323666200814132149.2020.

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. Nature. 2020;582:289-293.

DOI: 10.1038/s41586-020-2223-y.

Smith M, Smith JC. Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral Spike protein and viral Spike protein-human ACE2 interface. ChemRxiv. 2020:1-28. Available in: https : // articles/preprint/Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_ nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface/11871402.

Li F. Structure, function, and evolution of coronavirus Spike proteins. Annu Rev Virol. 2016;3(1):237-261.

DOI: 10.1146/annurev-virology-110615-042301.

Bian H, Zheng ZH, Wei D, Zhang Z, Kang WZ, Hao CQ, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. MedRxiv. 2020:1-21.

DOI: 10.1101/2020.03.21.20040691v3.

Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214.

DOI: 10.1073/pnas.1617020114.

Lung J, Lin YS, Yang YH, Chou YL, Shu LH, Cheng YC, et al. The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase.J Med Virol. 2020;92(6):693-697.

DOI: 10.1002/jmv.25761.

Mirza MU, Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 RNA-dependent RNA polymerase and Nsp13 helicase. J Pharm Anal. 2020;10(4):320-328.

DOI: 10.1016/j.jpha.2020.04.008.

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020:1-5.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.

DOI: 10.1016/j.cell.2020.02.052.

Prajapat M, Shekhar N, Sarma P, Avti P, Singh S, Kaur H, et al. Virtual screening and molecular dynamics study of approved drugs as inhibitors of Spike protein S1 domain and ACE2 interaction in SARS-CoV-2. J Mol Graph Model. 2020;101:107716,1-13.

DOI: 10.1016/j.jmgm.2020.107716.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-452.

DOI: 10.1038/s41591-020-0820-9.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.

DOI: 10.1126/science.abb2507.

Rocco A, Compare D, Coccoli P, Esposito C, Di Spirito A, Barbato A, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013;62(5): 766-773.

DOI: 10.1136/gutjnl-2012-302344.

Paltiel O, Falutz J, Veilleux M, Rosenblatt DS, Gordon K. Clinical correlates of subnormal vitamin B12 levels in patients infected with the human immunodeficiency virus. Am J Hematol. 1995;49(4):318-322.

DOI: 10.1002/ajh.2830490410.

Kaushik N, Anang S, Ganti KP, Surjit M. Zinc: a potential antiviral against hepatitis E virus infection? DNA Cell Biol. 2018;37(7):593-599.

DOI: 10.1089/dna.2018.4175.

Read SA, Parnell G, Booth D, Douglas MW, George J, Ahlenstiel G. The antiviral role of zinc and metallothioneins in hepatitis C infection. J Viral Hepat. 2018;25(5):491-501.

DOI: 10.1111/jvh.12845.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.